- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders...
Announces that SPL026, intravenous N,N-Dimethyltryptamine, with supportive therapy for the treatment ...
Further Composition of Matter protection for SPL028, the Company’s next candidate expected to enter the clinic...
Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- Small Pharma...
Building on strong foundations to take Small Pharma through development to commercial success Peter Rands to take on role as Chief Innovation &...
Progress continues apace with multiple trials expected to enter clinic later this year First US patent granted LONDON, July 15, 2022 (GLOBE NEWSWIRE)...
LONDON, United Kingdom, June 22, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology...
Reporting its financial results and continued progress across short-acting psychedelics portfolio Executive team and IP position strengthened LONDON,...
LONDON, May 30, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused...
- Appointment of Alastair Riddell as COO- Two new Composition of Matter patents granted for pipeline projects- Progress continues across short-acting...